GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-15
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT00096603
Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-05
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00095433
A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-02
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT00095225
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center (TORI), Bakersfield, California, United States
🇺🇸Kaiser Permanente Northern CA, Vallejo, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 5000
- Registration Number
- NCT00091663
- Locations
- 🇺🇸
Antelope Valley Cancer Center, Lancaster, California, United States
🇺🇸Cancer and Blood Institute Medical Group, Rancho Mirage, California, United States
🇺🇸Utah Hematology and Oncology, Ogden, Utah, United States
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-09-01
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT00090623
- Locations
- 🇺🇸
Trial Information Support Line, Denver, Colorado, United States
A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
- First Posted Date
- 2004-07-13
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 439
- Registration Number
- NCT00087529
A Safety and Efficacy Study of Xolair in Peanut Allergy
Phase 2
Terminated
- Conditions
- First Posted Date
- 2004-07-09
- Last Posted Date
- 2013-01-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00086606
- Locations
- 🇺🇸
Trial Information Support Line, Denver, Colorado, United States
A Study Evaluating Tarceva in Combination With Avastin Versus Avastin Alone in Treating Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00081614
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸Raleigh Hematology Oncology, Raleigh, North Carolina, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-03-26
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 83
- Registration Number
- NCT00080223
A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2008-06-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT00079742
© Copyright 2024. All Rights Reserved by MedPath